Literature DB >> 20417343

Prevention and treatment of high-altitude pulmonary edema.

Marco Maggiorini1.   

Abstract

We distinguish two forms of high altitude illness, a cerebral form called acute mountain sickness and a pulmonary form called high-altitude pulmonary edema (HAPE). Individual susceptibility is the most important determinant for the occurrence of HAPE. The hallmark of HAPE is an excessively elevated pulmonary artery pressure (mean pressure 36-51 mm Hg), caused by an inhomogeneous hypoxic pulmonary vasoconstriction which leads to an elevated pulmonary capillary pressure and protein content as well as red blood cell-rich edema fluid. Furthermore, decreased fluid clearance from the alveoli may contribute to this noncardiogenic pulmonary edema. Immediate descent or supplemental oxygen and nifedipine or sildenafil are recommended until descent is possible. Susceptible individuals can prevent HAPE by slow ascent, average gain of altitude not exceeding 300 m/d above an altitude of 2500 m. If progressive high altitude acclimatization would not be possible, prophylaxis with nifedipine or tadalafil for long sojourns at high altitude or dexamethasone for a short stay of less then 5 days should be recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417343     DOI: 10.1016/j.pcad.2010.03.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  25 in total

1.  Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation--independent of absolute altitude?

Authors:  Veronika Leichtfried; Daniel Basic; Martin Burtscher; Raffaella Matteucci Gothe; Uwe Siebert; Wolfgang Schobersberger
Journal:  Sleep Breath       Date:  2015-06-02       Impact factor: 2.816

2.  Acute high-altitude illness: a clinically orientated review.

Authors:  Tom Smedley; Michael Pw Grocott
Journal:  Br J Pain       Date:  2013-05

Review 3.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

4.  Interventions for preventing high altitude illness: Part 3. Miscellaneous and non-pharmacological interventions.

Authors:  Daniel Molano Franco; Víctor H Nieto Estrada; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2019-04-23

Review 5.  Mitochondrial dynamics in pulmonary arterial hypertension.

Authors:  John Ryan; Asish Dasgupta; Jessica Huston; Kuang-Huieh Chen; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2015-02-13       Impact factor: 4.599

Review 6.  Short-term responses of the kidney to high altitude in mountain climbers.

Authors:  Alexander S Goldfarb-Rumyantzev; Seth L Alper
Journal:  Nephrol Dial Transplant       Date:  2013-03-22       Impact factor: 5.992

Review 7.  Wilderness medicine.

Authors:  Douglas G Sward; Brad L Bennett
Journal:  World J Emerg Med       Date:  2014

Review 8.  Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).

Authors:  Isaac Solaimanzadeh
Journal:  Cureus       Date:  2020-03-20

9.  Nrf2 activation: a potential strategy for the prevention of acute mountain sickness.

Authors:  Christina Lisk; Joe McCord; Swapan Bose; Tim Sullivan; Zoe Loomis; Eva Nozik-Grayck; Thies Schroeder; Karyn Hamilton; David C Irwin
Journal:  Free Radic Biol Med       Date:  2013-05-27       Impact factor: 7.376

10.  Disturbed eating at high altitude: influence of food preferences, acute mountain sickness and satiation hormones.

Authors:  Isabelle Aeberli; Annina Erb; Kerstin Spliethoff; Daniela Meier; Oliver Götze; Heiko Frühauf; Mark Fox; Graham S Finlayson; Max Gassmann; Kaspar Berneis; Marco Maggiorini; Wolfgang Langhans; Thomas A Lutz
Journal:  Eur J Nutr       Date:  2012-05-10       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.